Based on the Addex Therapeutics Ltd stock forecast from 1 analysts, the average analyst target price for Addex Therapeutics Ltd is USD 30.00 over the next 12 months. Addex Therapeutics Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Addex Therapeutics Ltd is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Addex Therapeutics Ltd’s stock price was USD 7.99. Addex Therapeutics Ltd’s stock price has changed by +4.87% over the past week, +0.52% over the past month and +46.63% over the last year.
No recent analyst target price found for Addex Therapeutics Ltd
No recent average analyst rating found for Addex Therapeutics Ltd
Company Overview Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot"Marie"Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland. Read Less
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant...Read More
Frequently Asked Questions About Addex Therapeutics Ltd (ADXN) Stock
Based on ratings from 1 analysts Addex Therapeutics Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on ADXN's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ADXN is USD 30.00 over the next 12 months. The maximum analyst target price is USD 30 while the minimum anlayst target price is USD 30.
ADXN stock's Price/Earning ratio is -99,999.99.
Our analysis grades ADXN stock's Price / Earning ratio at A+. This means that ADXN stock's Price/Earning ratio is above 3.000000000000003% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ADXN may be undervalued for its sector.
The last closing price of ADXN's stock was USD 7.99.
The most recent market capitalization for ADXN is USD 8.71M.
Based on targets from 1 analysts, the average taret price for ADXN is projected at USD 30.00 over the next 12 months.
This means that ADXN's stock price may go up by +275.40% over the next 12 months.
We can't find any ETFs which contains Addex Therapeutics Ltd's stock.
As per our most recent records Addex Therapeutics Ltd has 23 Employees.
Addex Therapeutics Ltd's registered address is Chemin des Mines, 9, Geneva, Switzerland, 1202.
You can get more information about it from Addex Therapeutics Ltd's website at https://www.addextherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Negative earnings
The company had negative total earnings in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Addex Therapeutics Ltd (ADXN) Stock
Based on ratings from 1 analysts Addex Therapeutics Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on ADXN's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ADXN is USD 30.00 over the next 12 months. The maximum analyst target price is USD 30 while the minimum anlayst target price is USD 30.
ADXN stock's Price/Earning ratio is -99,999.99.
Our analysis grades ADXN stock's Price / Earning ratio at A+. This means that ADXN stock's Price/Earning ratio is above 3.000000000000003% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ADXN may be undervalued for its sector.
The last closing price of ADXN's stock was USD 7.99.
The most recent market capitalization for ADXN is USD 8.71M.
Based on targets from 1 analysts, the average taret price for ADXN is projected at USD 30.00 over the next 12 months.
This means that ADXN's stock price may go up by +275.40% over the next 12 months.
We can't find any ETFs which contains Addex Therapeutics Ltd's stock.
As per our most recent records Addex Therapeutics Ltd has 23 Employees.
Addex Therapeutics Ltd's registered address is Chemin des Mines, 9, Geneva, Switzerland, 1202.
You can get more information about it from Addex Therapeutics Ltd's website at https://www.addextherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ADXN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
